Episurf Medical reaches milestone of 900 implants

Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of the 900th surgery with the Episealer® knee implant. Close to 400 patients have had the implant for more than 2 years, and approximately 70 patients have passed 5 years since surgery. Clinical results from several clinical studies have recently been published, showing excellent clinical improvements and a low revision rate. 

“We are pleased to have reached this milestone at the end of the year. Despite a very challenging year for elective surgeries, our customers have continued to order Episealer® implants when possible. We are looking forward to continued growth, supported by strong clinical evidence”, says Pål Ryfors, CEO Episurf Medical. 

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Tags: